title: Liposomal doxorubicin: a phase II trial.
abstract: OBJECTIVE
  In patients with disseminated endometrial carcinoma, doxorubicin is used as a single agent or in combination therapy. We have carried out a phase II clinical trial of liposomal doxorubicin in first-line therapy of women with disseminated endometrial carcinoma.
  
  
  METHODS
  Between September 2001 and May 2003, 22 patients with histologically confirmed disseminated endometrial carcinoma, were enrolled in this study. Eleven patients had been previously treated with radiation, none of them had been treated with chemotherapy. Liposomal doxorubicin (40 mg/m2) was intravenously administered at 4 week intervals until toxicity or progression.
  
  
  RESULTS
  The most common adverse events were fatigue, anemia, pain, and dermatologic toxicity (EPP). Eight patients (36%) achieved a tumor regression (Complete response, CR 3; Partial response, PR 5), ten (46%) maintained stable disease, and four (18%) experienced increasing disease.
  
  
  CONCLUSIONS
  Liposomal doxorubicin has a lower cardiologic toxicity than doxorubicin with a similar response rate in patients with disseminated endometrial carcinoma.
authors.affiliation: Department Obstetrics and Gynecology, Second University of Study of Naples, Naples, Italy. giancarlo.balbi@unina2.it
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Balbi
authors.forename: Serena
authors.initials: S
authors.lastname: Visconti
authors.forename: Antonietta
authors.initials: A
authors.lastname: Monteverde
authors.forename: Maria-Amparo
authors.initials: MA
authors.lastname: Manganaro
authors.forename: Antonio
authors.initials: A
authors.lastname: Cardone
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018269:Carcinoma, Endometrioid / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D004717:Endometrium / Q000473:pathology; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin